We are the leading Spanish company marketing R&D products nationally and internationally.

Almirall in figures

Our figures are the result of combining an outstanding business structure, an excellent team of professionals, sound values, an international perspective and substantial investment in R&D, all resulting in a high quality product portfolio which allows us to offer the best therapeutic solutions for people all over the world.

Net sales Net sales

General data 2010

Net sales (*)

(in millions of euros)
Spanish market
495
Foreign market
387
Total
882
(*) Local sales, Almirall and partners.
Market share in Spain
5%
Percentage of proprietary products over total income
aprox 45%

Own R&D products

(geographical location)

  • Aceclofenac: Europe, Asia-Pacific, Africa, Middle East, Central America and South America.
  • Almagate: Europe, Asia-Pacific and Central America.
  • Almotriptan: Europe and North America.
  • Cinitrapide: Europe and Central America.
  • Clebopride: Europe and Asia-Pacific.
  • Ebastine: Europe,Africa, Asia-Pacific, Middle East, Central America and South America.
  • Piketoprofen: Europe.

Resources in R&D

  • Over 15% over net sales
  • Over 15% of the workforce

15 best-selling products

73% of sales in 2010 corresponded to the company's 15 best-selling products, with 4 of them being Almirall R&D products:

Active Ingredient Therapeutic Area Pathology
1 Ebastine * Respiratory Allergy
2 Atorvastatin Cardiovascular Cholesterol
3 Escitalopram Central nervous system Depression
4 Salmeterol + fluticasone Respiratory Asthma COPD
5 Almotriptan * Central nervous system Migraine
6 Candesartan cilexetil Cardiovascular Hypertension
7 Aceclofenac * Osteomuscular system Pain
8 Lansoprazole Gastrointestinal Ulcers
9 Venlafaxine Central nervous system Depression
10 Sitagliptin & sitagliptin + metformin Gastrointestinal Diabetes
11 Diclofenac sodium + hialuronic acid Dermatology Actinic keratoses
12 Almagate * Gastrointestinal Antacid
13 Soya oil Dermatology Atopic dermatitis
14 Pantoprazole Gastrointestinal Gastroesophageal reflux
15 Fluprednidene Dermatology Mycotic dermatitis

(*) Almirall R&D products

Workforce

(includes full time equivalence)
Total
2,831
Global R&D
523

Work centres

Headquarters

Barcelona

R&D

  • 3 R&D centres: Sant Feliu (Barcelona - Spain), Bad Homburg (Frankfurt - Germany) and Reinbek (Germany).
  • 2 Units: Chemical Synthesis in Sant Just Desvern and Active Ingredient Scale-up Unit in Sant Andreu de la Barca (Barcelona - Spain).

Production

5 centres:

  • 3 pharmaceutical plants in Sant Andreu de la Barca, Sant Just Desvern (Barcelona - Spain) and Reinbek (Germany).
  • 2 chemical plants in Sant Andreu de la Barca and Sant Celoni (Barcelona - Spain).